Voximetry and Y-mAbs, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radiopharmaceuticals and commercial-stage antibody-based therapeutic products for the treatment of cancer, have entered into a preferred provider agreement, Voximetry announced recently.

According to a release, y-mAbs designates Voximetry as a preferred provider for dosimetry services for radiopharmaceutical clinical trials.

“We are very pleased to be selected by Y-mAbs as a trusted partner, and we are proud to support their innovative pipeline with our tailored dosimetry services,” Voximetry CEO Sue Wallace said in a statement. “Our ability to help with pre-study design and accurate dose assessments, combined with Y-mAbs novel antibody-based therapeutics, will enable greater efficiency of the drug development process.”

Y-mAbs has two open and ongoing clinical trials.